Cytokinetics Stock Forecast, Price & News

-0.21 (-0.62 %)
(As of 09/16/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume608,863 shs
Average Volume1.22 million shs
Market Capitalization$2.80 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CYTK News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

Cytokinetics logo

About Cytokinetics

Cytokinetics, Inc. operates as a biopharmaceutical company. The firm focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

2.39 out of 5 stars

Medical Sector

174th out of 1,352 stocks

Pharmaceutical Preparations Industry

82nd out of 665 stocks

Analyst Opinion: 4.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

Is Cytokinetics a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cytokinetics stock.
View analyst ratings for Cytokinetics
or view top-rated stocks.

What stocks does MarketBeat like better than Cytokinetics?

Wall Street analysts have given Cytokinetics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cytokinetics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Cytokinetics?

Cytokinetics saw a increase in short interest during the month of July. As of July 30th, there was short interest totaling 11,920,000 shares, an increase of 32.4% from the July 15th total of 9,000,000 shares. Based on an average trading volume of 1,810,000 shares, the short-interest ratio is currently 6.6 days.
View Cytokinetics' Short Interest

When is Cytokinetics' next earnings date?

Cytokinetics is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Cytokinetics

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) issued its quarterly earnings results on Thursday, August, 5th. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.66) by $0.20. The biopharmaceutical company earned $2.84 million during the quarter, compared to analysts' expectations of $5.68 million. Cytokinetics had a negative net margin of 269.48% and a negative trailing twelve-month return on equity of 179.39%.
View Cytokinetics' earnings history

How has Cytokinetics' stock been impacted by COVID-19 (Coronavirus)?

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CYTK shares have increased by 178.4% and is now trading at $33.49.
View which stocks have been most impacted by COVID-19

What guidance has Cytokinetics issued on next quarter's earnings?

Cytokinetics issued an update on its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $23 million-$28 million, compared to the consensus revenue estimate of $28.07 million.

What price target have analysts set for CYTK?

11 analysts have issued 1-year price targets for Cytokinetics' shares. Their forecasts range from $16.00 to $58.00. On average, they expect Cytokinetics' stock price to reach $43.09 in the next year. This suggests a possible upside of 28.7% from the stock's current price.
View analysts' price targets for Cytokinetics
or view top-rated stocks among Wall Street analysts.

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the following people:
  • Robert I. Blum, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Eric Terhaerdt, Vice President-Development Operations
  • Ching W. Jaw, Chief Financial Officer & Senior Vice President
  • Fady Ibraham Malik, Executive Vice President-Research & Development (LinkedIn Profile)
  • Andy Wolff, Senior VP-Clinical Research & Development

What is Robert I. Blum's approval rating as Cytokinetics' CEO?

16 employees have rated Cytokinetics CEO Robert I. Blum on Robert I. Blum has an approval rating of 64% among Cytokinetics' employees.

Who are some of Cytokinetics' key competitors?

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (16.25%), FMR LLC (10.16%), Vanguard Group Inc. (5.66%), State Street Corp (5.09%), Wasatch Advisors Inc. (3.11%) and Integral Health Asset Management LLC (1.68%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Ching Jaw, David Cragg, Fady Ibraham Malik, John T Henderson, John T Henderson, L Patrick Gage, Mark A Schlossberg, Robert I Blum, Robert I Blum, Sandford D Smith, Sandford D Smith, Santo J Costa, Value Fund L P Biotechnology and Wendall Wierenga.
View institutional ownership trends for Cytokinetics

Which institutional investors are selling Cytokinetics stock?

CYTK stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., BlackRock Inc., Goldman Sachs Group Inc., Vanguard Group Inc., Marshall Wace LLP, Marshall Wace LLP, Bank of New York Mellon Corp, and Point72 Asset Management L.P.. Company insiders that have sold Cytokinetics company stock in the last year include Bvf Partners L P/Il, Ching Jaw, David Cragg, Fady Ibraham Malik, John T Henderson, L Patrick Gage, Robert I Blum, Sandford D Smith, and Santo J Costa.
View insider buying and selling activity for Cytokinetics
or view top insider-selling stocks.

Which institutional investors are buying Cytokinetics stock?

CYTK stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Commodore Capital LP, Logos Global Management LP, Integral Health Asset Management LLC, Squarepoint Ops LLC, State Street Corp, Northern Trust Corp, and Bank of America Corp DE. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology.
View insider buying and selling activity for Cytokinetics
or or view top insider-buying stocks.

How do I buy shares of Cytokinetics?

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $33.49.

How much money does Cytokinetics make?

Cytokinetics has a market capitalization of $2.80 billion and generates $55.83 million in revenue each year. The biopharmaceutical company earns $-127,290,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis.

How many employees does Cytokinetics have?

Cytokinetics employs 184 workers across the globe.

When was Cytokinetics founded?

Cytokinetics was founded in 1997.

What is Cytokinetics' official website?

The official website for Cytokinetics is

Where are Cytokinetics' headquarters?

Cytokinetics is headquartered at 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at (650) 624-3000 or via email at [email protected]

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.